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Background: Aim of the study was to assess QTc interval by a 24-hour ECG recording in a group of HIV-infected
individuals with a basal prolonged QTc. The risk factors associated with QTc prolongation and the indices of
cardiovascular autonomic control were also evaluated.
Methods: A case–control study was performed using as cases 32 HIV-infected patients with prolonged (>440 msec)
QTc interval as assessed by Holter ECG, and as controls 64 HIV-infected subjects with normal QTc interval.
Autonomic function was evaluated by heart rate variability analysis during 24-hour recording.
Results: Duration of HIV disease was significantly longer among cases than among controls (p=0.04). Waist/hip
ratio was also higher among cases than among controls (p=0.05). Frequency domain analysis showed the absence
of physiologic decrease of low frequency (LF) in the night period in both cases and controls. The LF night in cases
showed a statistically significant reduction when compared with controls (p=0.007).
Conclusions: In our study group, QTc interval prolongation was associated with a longer duration of HIV infection
and with a greater waist/hip ratio. HIV patients with QTc interval prolongation and with a longer duration of HIV
infection were more likely to have an impairment of parasympathetic and sympathetic cardiac component.
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QTc interval prolongation is an electrocardiographic
abnormality that may cause severe arrhythmias includ-
ing torsades de pointes and ventricular fibrillation. An
increased prevalence of QTc interval prolongation and a
longer QTc interval have been described among HIV-
infected patients when compared to HIV-negative sub-
jects [1-4]. QTc interval prolongation in HIV-positive
patients has been associated with several drugs [5-14], with
autonomic dysfunction due to HIV-associated neuropathy
[15,16], and with HCV coinfection [3]. The duration of
ventricular repolarization can change during the day
[17-19]; aim of the study was to assess QTc interval by
a 24-hour ECG recording in a group of HIV-infected* Correspondence: pierangelo.chinello@inmi.it
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reproduction in any medium, provided the orindividuals who presented a basal prolonged QTc. The risk
factors associated with QTc prolongation and the indices
of cardiovascular autonomic control were also evaluated.Methods
In the first phase of the study, 27 consecutive HIV-
infected patients with known prolonged QTc interval
(group I) as assessed by standard ECG recording, and 54
HIV-positive patients with normal QTc interval (group
II) matched 1:2 with group I individuals by gender and
age (± 5 years) underwent 24-hour Holter ECG record-
ing. QTc interval assessed by standard ECG recording
was defined as prolonged when >440 msec [20,21].
In the second phase of the study, a “nested” case–control
study was performed using as cases the 32 patients of both
group I and II with prolonged QTc interval as assessed by
Holter ECG, and as controls (1:2) 64 HIV infected subjects
with normal QTc interval as assessed by standard andral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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patients came from the original group II, and 24 were con-
secutive HIV-infected patients with normal QTc interval
at standard and Holter ECG recording. The algorithm of
the study is illustrated in Figure 1. QTc interval assessed
by Holter ECG recording was defined as prolonged when
its mean value was >440 msec.
For each subject the following data were ascertained:
demographic features; risk factors for HIV infection;
HIV clinical group according to the Centers for Disease
Control and Prevention (CDC), Atlanta, classification;
ongoing therapy and prophylaxis; excessive alcohol in-
take; cardiologic risk factors including diabetes, hyper-
tension, dyslipidemia, smoking habits, and family history;
CD4+ lymphocytes count, HIV viraemia and the results of
the main haematochemical tests including glycaemia,
serum electrolytes, total cholesterol, high-density lipopro-
tein-cholesterol, low-density lipoprotein-cholesterol, and
triglycerides. Hypertension was defined as a blood pres-
sure ≥140 mmHg systolic or ≥90 mmHg diastolic or
current use of antihypertensive medication [22]. Hyper-
cholesterolaemia was defined as a serum total choles-
terol level ≥200 mg/dL, hypertriglyceridaemia as a
serum triglyceride level ≥200 mg/dL, and diabetes as
fasting blood glucose of 126 mg/dL or greater [22].
Obesity was defined as a body mass index >30 kg/m2.
Excessive alcohol intake was defined as follows: for
women and persons >65 years of age, >7 standard drinks
per week or >3 drinks per occasion; for men ≤65 years of
age, >14 standard drinks per week or >4 drinks per
occasion; a standard drink is approximately 12 to 14 g of
ethanol [23].Figure 1 Algorithm of the study.All subjects, during ECG Holter registration, spent on
average 8 h in bed, from 11 p.m. to 7 a.m. ECG Holter
was analysed for 24 hours, at 10 minutes interval. Artificial
data and arrhythmic events were excluded. Autonomic
nervous system function was evaluated by heart rate vari-
ability (HRV) analysis during 24-hour ECG recording. All
Holter recordings were performed using a three-channel
recorder. Cardiovascular variability was analysed following
the recommendations of the Task Force of the European
Society of Cardiology and the North American Society of
Pacing and Electrophysiology [24].
Spectral estimated of R-R interval were obtained from
stationary regions free of ectopic beats and technical
artifacts. The standard deviation of normal-to-normal
RR intervals [SDNN (ms), correlated with total auto-
nomic activity] and the square root of the mean of the
sum of the squares of differences between adjacent NN
intervals [RMS-SD (ms), correlated with parasympa-
thetic system] were calculated and were divided in two
period: night (0 am – 6 am) and day (7 am – 11 pm).
Fast Fourier Transform was used to obtain power spec-
tral estimates of HRV; total power in the frequency
range (0–0.40 Hz) was divided into: very low frequency
(VLF: < 0.04 Hz), low frequency (LF: 0.04–0.15 Hz,
modulated by sympathetic system), and high frequency
(HF: 0.15–0.40 Hz, mediated by parasympathetic sys-
tem). The integral under respective power density func-
tions were measured and were expressed in absolute
units (ms2/Hz). Each spectral component was presented
in normalized units (n.u.) by dividing LF or HF by total
power minus the very low frequency (LF or HF/total
power – VLF). LF/HF ratio, considered an index of
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also calculated. We examined HRV during 24 hours
(total HRV), in the night time (0 am -6 am) and in the
day time (7 am -11 pm).
The program calculates the QT interval from begin-
ning of QRS to the end of the T wave. The end of the T
wave was defined as the point of maximal change in the
slope as the T wave merges with the baseline. QT inter-
val was corrected for heart rate by calculating QTc. QTc
was calculated by Bazett’s equation [QTc = QT/RR1/2]
and was controlled by at least two physicians (L.T., A.F.,
A.D.S, and L.B.).
Data analyses were performed by Del Mar Avionics
Accuplus 363, Irvine California, USA. In ten healthy
subjects reproducibility was evaluated by means of the
interclass correlation coefficient (ICC) comparing base-
line values with the results obtained at the fourth week
ICC was more > 0.7 for HRV.
Informed consent was obtained from all participants;
all the investigations were performed in accordance with
the principles of the Declaration of Helsinki. The re-
search was approved by the Ethics Committee of “L.
Spallanzani” National Institute for Infectious Diseases,
Rome (Italy).
Statistical analysis was performed by SPSS 13.0 (SPSS
Inc., Chicago, IL, U.S.A.) for Windows XP. Correlation
between discrete and continuous variables were assessed
by chi-square ant t-student tests, respectively. Paramet-
ric data were expressed as means ± standard deviation.
A p ≤ 0.05 was considered as statistically significant.
Results
Twenty-seven consecutive HIV-infected patients (group
I) with known prolonged QTc interval (mean 464±23
msec) assessed by ECG recording at a previous study
[25] underwent 24-hour Holter ECG recording. Twenty-
one of them were males, their mean age was 46.6±9.5
years, and they were HIV positive since 10.5±6.4 years.
Eighteen out of 27 patients (67%) had QTc interval pro-
longation confirmed by Holter ECG recording, while 9/27
(33%) showed a normal QTc interval at Holter ECG.
The 54 patients of group II had a normal QTc interval
(mean 406±20 msec) assessed by standard ECG; they
were 42 males and 12 females, HIV positive since 8.6
±6.8 years, with a mean age of 46±9.2 years. Fourty of
them (74%) had a normal QTc interval confirmed by
Holter ECG recording, while 14/54 (26%) showed a pro-
longed QTc interval at Holter ECG.
Overall, 32 patients from both group I and II had a
prolonged QTc interval (mean 475±33 ms) assessed by
Holter ECG recording and were considered cases. They
were matched by gender and age (± 5 years) with 64
controls exhibiting a normal QTc interval assessed by
Holter ECG. The main demographic and clinical featuresof cases and controls are described in Table 1. Neither
cases nor controls complained of angina or dyspnoea.
Thirteen patients among cases (41%) and 17 among con-
trols (26%) presented ectopic ventricular beats (p=0.2);
14 patients among cases (44%) and 30 among controls
(47%) presented ectopic supraventricular beats (p=0.9).
Duration of HIV disease was significantly longer among
cases than among controls (10.9±7.1 years vs 7.8±6.4
years; p = 0.04). Cases were more frequently alcohol
abusers than controls, although at a not statistically sig-
nificant level (16% vs 5%; OR 3.77, 95% C.I. 0.71-21.74;
p = 0.1). Waist/hip ratio was higher among cases than
among controls (0.93±0.07 vs 0.90±0.07; p = 0.05).
Among cases, after a mean follow-up of 4.8±0.9 years 5
patients resulted dead and 27 were still alive; among
controls, after a mean follow-up of 4.1±1.1 years 2
patients resulted dead and 62 were still alive (p=0.04).
Antiretroviral drugs were not associated with QTc
prolongation at a statistically significant level (Table 2).
However, patients treated with zidovudine (AZT) pre-
sented QTc prolongation more frequently than patients
not treated with AZT (34% vs 19%; OR 2.27 and 95% C.
I. 0.78-6.62; p=0.15). Moreover, patients receiving emtri-
citabine (FTC) were less likely to have a QTc prolonga-
tion than patients not receiving FTC (12% vs 31%; OR
0.31 and 95% C.I. 0.08-1.12; p=0.08).
Table 3 illustrates the indices of cardiovascular auto-
nomic control among cases and controls. Time domain
analysis showed a reduction of total SDNN in cases and
controls versus normal value, without statistically sig-
nificant differences between the two groups (p=0.320).
Frequency domain analysis showed the absence of
physiologic decreased of LF in the night period in both
cases and controls. The LF night in cases showed a
statistically significant reduction when compared with
controls (p=0.007).
Discussion
One third of our HIV-infected patients with known QTc
prolongation measured by standard ECG recording
showed a normal QTc interval when assessed by Holter
ECG. Conversely, one fourth of our HIV-infected patients
with a normal QTc interval measured by standard ECG
had a prolonged QTc interval at Holter ECG. Beat-to-beat
QTc interval measurements from 24-hour ECG record-
ings may provide additional information since cardiac
autonomic nervous activity can modulate the variations
of ventricular repolarization [18]. Data on variations of
ventricular repolarization over time among HIV-infected
patients are scanty [26].
In our patients, a significant relationship was found
between duration of HIV infection and QTc interval pro-
longation. Such an association was previously reported by
Charbit and coll [27]. The reasons for this relationship are







Gender M 23 (72%) 46 (72%) 0.8
Age (years)* 45.7±7.6 45±9.9 0.6
BMI ≥25 15 (47%) 22 (34%) 0.3
< 25 17 (53%) 42 (66%)
CDC stage A+B 22 (69%) 46 (72%) 0.9
C 10 (31%) 18 (28%)
Years since HIV diagnosis* 10.9±7.1 7.8±6.4 0.04
Risk factors for HIV infection
IVDU 8 (25%) 10 (16%) 0.3
MSM 7 (22%) 19 (30%)
Eterosexual 16 (50%) 35 (54%)
other 1 (3%) 0
Arterial hypertension 4 (12%) 13 (20%) 0.5
Current smokers 18 (56%) 36 (56%) 0.8
Diabetes 0 0
Hypertriglyceridaemia 7 (22%) 17 (26%) 0.8
Hypercholesterolaemia 7 (22%) 18 (28%) 0.7
Alcohol abuse 5 (16%) 3 (5%) 0.1
Familiarity for IHD 10 (31%) 23 (40%) 0.8
Waist circumference (cm)* 90.6±12.5 87.0±10.0 0.16
Hip circumference (cm)* 97.3±10.4 96.0±6.9 0.5
Waist/hip ratio* 0.93±0.07 0.90±0.07 0.05
Active drug abuse 3 (9%) 3 (5%) 0.4
Methadone therapy 2 (6%) 3 (5%) 1
Prophylaxis with
cotrimoxazole
3 (9%) 8 (12%) 0.7
Ongoing ART 28 (87%) 53 (83%) 0.7
Type of ART
-PI-based 12 (37%) 26 (41%) 0.4
-NNRTI-based 13 (41%) 25 (39%)
-3 NRTI 3 (9%) 2 (3%)
HCV positive 8 (25%) 12 (19%) 0.6
HBsAg positive 1 (3%) 1 (2%) 1
Na (mEq/L)* 139±3.2 139±3.9 1
K (mEq/L)* 4,2±0.4 4,3±0.3 0.2
Ca (mg/dL)* 9,2±0.6 9,1±0.5 0.4
CD4+ lymphocytes/mmc* 501±214 490±264 0.8
HIVRNA (cp/mL)
<50 23 (72%) 45 (70%) 0.9
≥50 9 (28%) 19 (30%)
QTc interval (ms)* 475±33 401±23 <0.0001
Table 1 Demographic and clinical features of cases and
controls (Continued)
Ectopic ventricular beats 13 (41%) 17 (26%) 0.2
Ectopic supraventricular beats 14 (44%) 30 (47%) 0.9
*: mean±SD; BMI: body mass index; IVDU: intravenous drug users; MSM: men
having sex with men; IHD: ischaemic heart disease; ART: antiretroviral therapy;
PI: protease inhibitors; NNRTI: non-nucleoside reverse transcriptase inhibitors;
NRTI: nucleoside reverse transcriptase inhibitors.
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tion or cumulative exposure to anti-HIV drugs on the
heart and the autonomic nervous system [27]. Indeed,
autonomic neuropathy has been associated with QTc
interval prolongation in HIV-infected patients [15] and
asymptomatic alterations of the sympatho-vagal balance
can occur at the early stage of the disease, although they
are more severe in the advanced stage of HIV infection
[28,29]. Moreover, a selective autonomic neuropathy has
been associated to the adipose redistribution syndrome in
HIV-infected patients [30]. The increased waist/hip ratio
observed in our HIV-positive patients with QTc prolonga-
tion could suggest a link between autonomic dysfunction,
lipodystrophy, and QTc prolongation.
In our study population, antiretroviral drugs were not
significantly associated with QTc interval prolongation.
However, patients receiving AZT had an increased risk
of QTc interval prolongation (OR 2.27), although at a
not statistically significant level. AZT has been shown to
prolong the QT interval in rats by activating reactive
oxygen species formation in the heart mitochondria [31].
Conversely, patients receiving FTC were less likely to
have a QTc interval prolongation (OR 0.31); we did not
find any work in the literature reporting an association
between FTC and QTc interval alteration. The limited
sample size could have influenced the lack of statistical
significance in our findings.
Our group of HIV-infected patients with prolonged QTc
showed at follow-up an increased risk of death when com-
pared with patients with normal QTc (p=0.04). Interest-
ingly, none of the patients died for heart-related diseases.
Our data suggest a possible association between QTc pro-
longation and all-cause mortality also in HIV-infected
patients, likewise previously described among other non-
HIV populations [32].
The HRV analysis showed a sympathetic and parasym-
pathetic dysfunction, as demonstrated by the reduction
of global autonomic system (evaluated by SDNN value)
and an impairment of parasympathetic component in
night time with loss of circadian rhythms both in group
of HIV-infected patients with and without QTc interval
prolongation. However, in HIV-infected patients with
QTc interval prolongation we observed a relative reduc-
tion in night time of LF spectral component (pseudo
normalization) related to an impairment in sympathetic
Table 2 Antiretroviral drugs and QTc prolongation
Drug Cases (n=32) Controls (n=64) p
Zidovudine
Yes 11 12 0.15
No 21 52
Lamivudine
Yes 17 28 0.5
No 15 36
Tenofovir
Yes 15 35 0.6
No 17 29
Emtricitabine
Yes 4 20 0.08
No 28 44
Emtricitabine+tenofovir
Yes 4 20 0.08
No 28 44
Zidovudine+lamivudine
Yes 7 11 0.8
No 25 53
Didanosine
Yes 4 4 0.4
No 28 60
Abacavir
Yes 3 4 0.6
No 29 60
Efavirenz
Yes 11 20 0.9
No 21 44
Nevirapine
Yes 3 6 1
No 29 58
Atazanavir
Yes 6 16 0.6
No 26 48
Fosamprenavir
Yes 2 2 0.6
No 30 62
Lopinavir/ritonavir
Yes 2 5 1
No 30 59
Table 3 Indices of cardiovascular autonomic control
Cases (n=32) Controls (n=64) p
LF/HF ratio 2,78 ± 1,08 2,91 ± 1,23 0,306
LF (n.u.) 58, 48 ± 10,35 60,73 ± 9,68 0,151
HF (n.u.) 31,10 ± 7,43 30,72 ± 7,29 0,404
LF/HF ratio day 3,26 ±1,25 3,26 ± 1,43 0,491
LF day (n.u.) 62,91 ± 10,81 63,64 ± 10,81 0,378
HF day (n.u.) 26,85 ± 7,69 27,32 ± 7,26 0,385
LF/HF ratio night 1,90 ± 1,06 2,30 ± 1,14 0,050
LF night (n.u.) 50,30 ± 12,94 56,46 ± 10,41 0,007
HF night (n.u.) 38,76 ± 9,45 35,78 ± 9,46 0,077
SDNN (ms) 119,23 ± 38,64 122,93 ± 34,92 0,320
SDNN day (ms) 87,61 ± 25,14 97,26 ± 41,00 0,114
SDNN night (ms) 90,17 ± 27,66 104,22 ± 30,52 0,016
RMSSD (ms) 37,45 ± 14,74 40,49 ± 16,22 0,190
RMSSD day (ms) 36,16 ± 18,25 37,49 ± 16,00 0,358
RMSSD night (ms) 41,05 ± 18,00 43,23 ± 20,38 0,306
Results are expressed as mean ± SD for each variable. LF: low frequency; HF:
high frequency; LF/HF: low frequency/high frequency; n.u.: normalized units;
SDNN: standard deviation of all sinus rhythm RR intervals; RMSSD: the square
root of the mean of the sum of the squares of differences between adjacent
NN intervals; night time: 0–6 am, day time: 7 am–11 pm.
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group of HIV-infected patients with QTc interval pro-
longation the longer duration of HIV infection could
have a significant impact not only on parasympathetic
cardiac regulation but also on sympathetic cardiaccomponent with a down regulation. We suggest that an
accurate valuation of autonomic cardiac system in HIV-
infected patients with a long duration of HIV infection
could be advisable.
Our work presents some limitations: the number of
patients in both groups is limited, and the statistical dif-
ferences marginal; moreover, no echocardiographic data
are provided. However, to the best of our knowledge,
this seems to be the largest group of adult HIV-infected
patients ever studied by 24-hour Holter ECG recording.Conclusion
In conclusion, in our study group of HIV-infected
patients the QTc interval prolongation was assessed by
24-hour Holter ECG recording and was associated with
a longer duration of HIV infection and with a greater
waist/hip ratio. Further studies are needed to clarify the
role of antiretroviral drugs in the development of QTc
interval prolongation when assessed by Holter ECG
recording. Moreover, HIV-infected patients with QTc
interval prolongation and with a longer duration of HIV
infection were more likely to have an impairment of
parasympathetic and sympathetic cardiac component.
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